Major players in the wearable injectors market are Amgen, Becton, Dickinson, and Co, Enable Injections, Insulet Corporation, Ypsomed, Medtronic, Tandem Diabetes Care, Valeritas, and West Pharmaceutical Services.

New York, May 24, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Wearable Injectors Global Market Report 2022" - https://www.reportlinker.com/p06280913/?utm_source=GNW


The global wearable injectors market is expected to grow from $6.24 billion in 2021 to $7.16 billion in 2022 at a compound annual growth rate (CAGR) of 14.8%. The market is expected to grow to $11.29 billion in 2026 at a compound annual growth rate (CAGR) of 12.0%.

The wearable injectors market consists of sales of wearable injectors and related services by entities (organizations, sole traders, and partnerships) that manufacture wearable injectors.Wearable injectors are drug delivery devices that adhere to the body while the drug is administered subcutaneously over a preset time duration.

Only goods and services traded between entities or sold to end consumers are included.

The main types of wearable injectors are on-body injectors and off-body injectors.On-body injectors are drug delivery devices that are applied directly to the patient’s skin, in the abdominal region or the back of the patient’s arm.

The various applications include immuno-oncology, diabetes, cardiovascular diseases, and others that are used by various end-users such as hospitals, clinics, and home care settings.

North America was the largest region in the wearable injectors market in 2021.Western Europe was the second-largest region in the wearable injectors market.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The rise in the number of diabetic and chronic diseases patients such as cardiovascular diseases and cancers contributed to the growth of the wearable injectors market.According to the International Diabetes Federation, in 2019, approximately 463 million adults were living with diabetes, and by 2045, it is estimated that around 700 million adults around the world and 1 in 5 adults who are above 65 are expected to suffer from diabetes.

The rise in the number of diabetes and chronic diseases patients increased the demand for the treatment of the diseases, thereby driving the wearable injectors market.

The high cost associated with wearable injectors is expected to limit the growth of the wearable injectors market.According to Drug Development and Delivery, wearable injectors are single-use systems that are comfortably worn on the body that costs between $20 to $35 per unit, which is high.

The high cost associated with wearable injectors has a negative impact on the wearable injectors market growth.

The focus areas for many companies in the wearable injectors manufacturing market have shifted to increasing mergers and acquisitions to acquire more production capabilities.Large prime manufacturers are forming joint ventures or buying small or midsized companies to acquire new capabilities or gain access to new markets.

For instance, in April 2020, Zealand Pharma completed its acquisition of Valeritas, Inc., to expand the product portfolios and capabilities of the company. The acquisition is expected to build Zealand Pharma’s capabilities and significantly increase its market share in the market. For instance, in April 2020, Zealand Pharma completed its acquisition of Valeritas, Inc., with an undisclosed amount. This acquisition helps to expand the product portfolios and capabilities of the company and is expected to build Zealand Pharma’s capabilities and to importantly increase its market share in the market. Valeritas is a medical technology company committed to improving and commercializing creative drug delivery solutions.

In April 2020, Copenhagen-based Zealand Pharma, a company that develops therapies for gastrointestinal, metabolic diseases, acquired Valeritas a New Jersey-based company that developed wearable insulin delivery devices for a deal amount of $23 million, plus the assumptions of some liabilities.The acquisition is expected to expand the footprint of Zealand Pharma in the US diabetes market.

Valeritas, Inc is a medical technology company headquartered in the United States.

The countries covered in the wearable injectors market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.


Read the full report: https://www.reportlinker.com/p06280913/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001